STOCK TITAN

BIOHARVEST SCIENCES NEW - CNVCD STOCK NEWS

Welcome to our dedicated page for BIOHARVEST SCIENCES NEW news (Ticker: CNVCD), a resource for investors and traders seeking the latest updates and insights on BIOHARVEST SCIENCES NEW stock.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) is a pioneering company utilizing its patented Botanical Synthesis technology platform to grow plant-based molecules without the need to grow the underlying plant. The company's flagship product VINIA® achieved record monthly sales orders in May 2024, demonstrating a 101% increase year-over-year. This growth can be largely attributed to the success of the Direct-to-Consumer sales strategy and the introduction of 'VINIA® Inside' products, such as VINIA® Superfood Coffee. With a focus on creating products with superior efficacy based on real science, BioHarvest is committed to expanding its product line to include new delivery systems and, with the upcoming completion of its Hot Beverage Strategy for 2024, expects robust revenue growth in the quarters ahead.

Rhea-AI Summary

BioHarvest Sciences (CSE: BHSC, OTCQB: CNVCD, FSE: 8MV) has successfully closed the first tranche of its private placement, raising USD $4,329,982.62. The company issued 603,904 share units at USD $7.17 per unit. Each unit includes one common share, one-quarter of a USD $7.68 warrant expiring in 6 months, and one-quarter of a USD $11.52 warrant expiring in 18 months. These funds will support the CDMO business unit, expand manufacturing capabilities, and cover general corporate expenses.

Additionally, BioHarvest announced the conversion of CAD $288,933.09 in convertible debt notes from previous financing rounds into 33,697 common shares. The company also issued 20,242 'Early Exercise' warrants at USD $7.70, expiring on December 22, 2025. Over 93% of the company's convertible notes have now been exercised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
private placement
-
Rhea-AI Summary

BioHarvest Sciences is set to present at the Noble Capital Markets Virtual Equity Conference on June 27, 2024. CEO Ilan Sobel will host virtual one-on-one meetings with institutional investors and deliver a presentation at 1:30 p.m. Eastern time. The event is open for media and investor registration via the provided link, and the presentation will be available as a video webcast post-event on BioHarvest's website and ChannelChek. The webcast will be archived on Channelchek.com for 90 days. For more information or to schedule a meeting, contact MZ Group.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
conferences
-
Rhea-AI Summary

BioHarvest Sciences announced a private placement of up to USD $5 million, offering 697,350 units at USD $7.17 per unit. Each unit includes one common share and warrants allowing purchase at USD $7.68 and USD $11.52 within specified periods. The funds will support the expansion of their CDMO business and general corporate purposes. Additionally, the company converted CAD $1.33 million of debt notes into 161,620 common shares, issuing 114,236 early exercise warrants. Over 90% of their convertible notes have now been exercised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
private placement
Rhea-AI Summary

BioHarvest Sciences, a leader in Botanical Synthesis technology, is set to present at the Sidoti Small-Cap Virtual Investor Conference on June 13, 2024. CEO Ilan Sobel will hold virtual one-on-one meetings with institutional investors and deliver a presentation at 11:30 a.m. Eastern time. Interested parties can join the presentation via a live webcast. Registration is required for participation, and an archive of the presentation will be available for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Rhea-AI Summary

BioHarvest Sciences has reported record monthly sales of $1.98 million for May 2024, driven by a 101% year-over-year increase in sales orders for its VINIA product. This growth was primarily fueled by strong subscription rates and the introduction of new products like VINIA Superfood Coffee.

The company has also surpassed 5,000 customer reviews, with an average rating of 4.8 out of 5. CEO Ilan Sobel highlighted the effectiveness of their Direct-to-Consumer strategy and the potential for further revenue growth through new product lines and marketing programs.

BioHarvest aims to achieve revenues of $5.7-6.0 million for Q2 2024 and is targeting a Nasdaq uplisting by the end of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none

FAQ

What is the current stock price of BIOHARVEST SCIENCES NEW (CNVCD)?

The current stock price of BIOHARVEST SCIENCES NEW (CNVCD) is $6.025 as of July 2, 2024.

What is the market cap of BIOHARVEST SCIENCES NEW (CNVCD)?

The market cap of BIOHARVEST SCIENCES NEW (CNVCD) is approximately 103.7M.

What technology platform does BioHarvest Sciences use?

BioHarvest Sciences utilizes its patented Botanical Synthesis technology platform to grow plant-based molecules without growing the underlying plant.

What was the record sales achievement of VINIA® in May 2024?

VINIA® achieved record monthly sales orders of US$1.98M in May 2024, representing a 101% increase compared to May 2023.

What contributed to the sales growth of BioHarvest's Products division?

The sales growth was primarily driven by strong VINIA® subscription rates, with a significant increase in nutraceutical capsule business as well as 'VINIA® Inside' products.

How does BioHarvest plan to expand its revenue?

BioHarvest plans to expand its revenue by introducing new 'VINIA Inside' delivery systems and completing its Hot Beverage Strategy for 2024, among other initiatives.

What is BioHarvest's approach to customer feedback?

BioHarvest values honest and uncensored customer feedback, encouraging all customers to leave reviews. Positive customer feedback is a key component in both word-of-mouth and corporate marketing programs.

What are some upcoming products in BioHarvest's pipeline?

BioHarvest is formulating and testing VINIA® Hydration Powder and Skincare products, which will be the Company's first Sports Performance and Skin Health products.

What revenue expectations does BioHarvest have for the second quarter of 2024?

BioHarvest expects revenues to be in the range of $5.7-6.0 million in the second quarter of 2024.

What is the focus of BioHarvest's Direct-to-Consumer Products strategy?

BioHarvest's Direct-to-Consumer Products strategy aims to create superior science-based and clinically proven therapeutic solutions within the nutraceutical health and wellness products sector.

What does BioHarvest offer as a contract development and production organization (CDMO)?

BioHarvest acts as a CDMO on behalf of customers seeking complex molecules, providing development and production services using its patented technology platform.

What are the key factors affecting BioHarvest's financial performance?

The financial performance of BioHarvest is dependent on factors such as supply chain efficiencies, input cost stability, marketing efficiencies, and consumer preferences, among others.

BIOHARVEST SCIENCES NEW

OTC:CNVCD

CNVCD Rankings

CNVCD Stock Data

103.71M
United States of America